Clinical Trials

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03381274 2026-03-11

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

43 enrolled 30 charts

Carcinoma, Non-Small-Cell Lung

NCT06194448 2026-03-06

NEOLA

76 enrolled

Lung Neoplasms

NCT05526755 2026-03-04

TARGET

188 enrolled

Stage II-IIIB Non-small Cell Lung Carcinoma

NCT06417814 2026-03-02

TROPION-Lung15

Phase 3 Recruiting

744 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03521154 2026-02-27

LAURA

216 enrolled 25 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03940703 2026-02-27

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

140 enrolled 47 charts

Carcinoma, Non-Small-Cell Lung

NCT04606771 2026-02-27

CoC

30 enrolled 20 charts

GastrointestinalHead & NeckThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05647122 2026-02-20

EGRET

Phase 1 Recruiting

403 enrolled

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasms, Colorectal Neoplasms

NCT04868877 2026-02-19

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Phase 1/2 Active not recruiting

194 enrolled

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06970639 2026-02-12

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

Phase 3 Recruiting

380 enrolled

NSCLC Patients With Brain Metastasis

NCT03778229 2026-02-10

SAVANNAH

367 enrolled 32 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT02917993 2026-02-09

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Phase 1/2 Completed

59 enrolled

Carcinoma, Non-Small-Cell Lung, Inhibition, Psychological, Lung Neoplasms, Neoplasm Metastasis

NCT04487080 2026-02-04

MARIPOSA

1,074 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03040973 2026-02-02

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

29 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07376382 2026-02-02

SYNSTAR-02

450 enrolled

Phase 1 Active not recruiting

NSCLC

NCT02143466 2026-01-30

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

344 enrolled

Advanced Non Small Cell Lung Cancer

NCT05546866 2026-01-27

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

51 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05816252 2026-01-27

MK-2870-003

356 enrolled

Phase 1 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07005102 2026-01-23

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

694 enrolled

Tumor-Agnostic

Neoplasms

NCT07361705 2026-01-23

Zorifertinib With Osimertinib for NSCLC With Meningeal Progression

42 enrolled

CNS

Meningeal Carcinomatosis

NCT04486833 2026-01-21

Acclaim-1

Phase 1/2 Recruiting

158 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02411448 2026-01-16

RELAY

545 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04765059 2026-01-13

COMPEL

98 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT05120349 2026-01-12

ADAURA2

390 enrolled

674 enrolled 21 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02296125 2026-01-09

FLAURA

Phase 3 Completed

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT02442349 2026-01-09

AURA17

Phase 2 Completed

171 enrolled 14 charts

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07329322 2026-01-09

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02511106 2026-01-05

ADAURA

682 enrolled 20 charts 2 FDA

Stage IB-IIIA Non-small Cell Lung Carcinoma

NCT07315113 2026-01-02

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Phase 1 Recruiting

18 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05629234 2025-12-24

ROSY-T

37 enrolled

Tumor-Agnostic

Neoplasms

NCT07079475 2025-12-24

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

Phase 1/2 Recruiting

200 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07295821 2025-12-22

NSCLC

60 enrolled